Open AccessTrabectedin therapy as an emerging treatment strategy for recurrent platinum‐sensitive ovarian cancer
Author(s) -
LópezGuerrero José Antonio,
Romero Ignacio,
Poveda Andrés
Publication year - 2015
Publication title -
cancer communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.119
H-Index - 53
ISSN - 2523-3548
DOI - 10.5732/cjc.014.10278
Subject(s) - trabectedin , medicine , oncology , ovarian cancer , debulking , chemotherapy , doxorubicin , cancer , surgery , soft tissue sarcoma , soft tissue
Abstract Epithelial ovarian cancer (OC) is a common gynecologic malignancy in women. The standard treatment for OC is maximal cytoreductive surgical debulking followed by platinum‐based chemotherapy. Despite the high response rate to primary therapy, approximately 85% of patients will develop recurrent ovarian cancer (ROC). This review identifies the clinical use of trabectedin in the treatment algorithm for ROC, with specific emphasis on platinum‐sensitive ROC, for which trabectedin in combination with pegylated liposomal doxorubicin has been approved as a treatment protocol. The main mechanisms of action of trabectedin at the cellular level and in the tumor microenvironment is also discussed as bases for identifying biomarkers for selecting patients who may largely benefit from trabectedin‐based therapies.